PLUS Study

Dr Swapnil Pawar February 8, 2022 440

share close
  • cover play_arrow

    PLUS Study
    Dr Swapnil Pawar

Join us for our 90th episode of the eCritCare podcast, where Jose Chacko & I discuss the recently published landmark trial PLUS. This trial demonstrated no significant difference in 90-day mortality between the saline group and the plasmalyte-148 group.

It raises the question – Does the choice of IV fluid in ICU really matter?

Should we stop worrying about the choice of fluid and focus on not giving so-called “maintenance fluids” to critically ill patients?

The key message is “anything in excess is bad, don’t give something that patient doesn’t need.”

Rate it
Previous episode
eCritCare Podcast
share playlist_add
  • 284


MICHELLE Trial – Rivaroxaban in COVID-19

Dr Swapnil Pawar January 30, 2022

play_arrow MICHELLE Trial – Rivaroxaban in COVID-19 Dr Swapnil Pawar Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial Blog Written […]

Read more trending_flat

Similar episodes